GERN earnings date and last-quarter result: last quarter in line, P/E -13.52. Updated 2026-07-23.
Geron (GERN) Research Hub
Geron (GERN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 1.15 USD (+2.68%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -13.52, market cap 0.90B. This hub links to the full technical, earnings and options research available for GERN.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.15 USD (+2.68%) |
| 52-week range | 1.08 USD – 1.65 USD |
| Trend regime | Range |
| 14-day RSI | 42.5 (Bearish) |
| Trailing P/E | -13.52 |
| Market cap | 0.90B |
| Dividend yield | 0.00% |
Available research for GERN
Covered Call on GERN: how it works, illustrative setup around the real 1.15 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on GERN: how it works, illustrative setup around the real 1.15 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on GERN: how it works, illustrative setup around the real 1.15 USD price, max profit/loss, breakeven and when to use it. Educational.
GERN technical analysis: range, last 1.15 USD, RSI 42.5, 52w range 1.08 USD–1.65 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is GERN in?
Geron (GERN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is GERN in an uptrend or downtrend?
As of 2026-10-26, GERN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is GERN's trailing P/E ratio?
GERN's trailing P/E is -13.52, with a market cap of 0.90B. See the earnings research page for full valuation detail.